PhD Supervisor, Chief Physician, Professor, and Head of the Endocrinology Department at the First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital).
Recipient of the Second Prize of Anhui Natural Science Award once and the Second Prize of Anhui Science and Technology Progress Award twice. Recognized as a Jianghuai Distinguished Doctor and receives a State Council special allowance.
Education and Work Experience
- 1982–1987: Bachelor’s Degree in Clinical Medicine, Wannan Medical College
- 1990–1993: Master’s Degree in Endocrinology, Shanghai Medical University
- 1993–1995: PhD in Endocrinology, Shanghai Medical University
- 1995–1997: Attending Physician, Internal Medicine, Anhui Provincial Hospital
- 1997–2002: Associate Chief Physician and Associate Professor, Endocrinology, Anhui Provincial Hospital
- 2002–2017: Chief Physician and Professor, Endocrinology, Anhui Provincial Hospital
- 2017–Present: Professor, Endocrinology, First Affiliated Hospital of USTC
Academic Achievements and Impact
Dedicated over 30 years to clinical practice, teaching, and research in endocrine metabolic diseases. Supervised 14 PhD and 65 master's students. Published 500 papers in domestic and international journals, with over 60 in SCI journals. Authored 6 academic books and contributed to 7 others.
Currently a member of the Diabetes Branch of the Chinese Medical Association and Chair of the Diabetes Branch of the Anhui Medical Association. Former Chair of the Endocrinology and Internal Medicine Branches of the Anhui Medical Association.
Ongoing Projects (Principal Investigator Only)
| Project Name | Source | Funding ID | Total Funding (10,000 RMB) | Duration |
| Clinical Study on Intensive Insulin Therapy for Type 2 Diabetes | Ministry of Science and Technology, Central Government Guided Local Science and Technology Innovation Special | 50 | 2017-09 to 2020-12 |
Main Research Directions (Recruitment Specialties) and Content
Clinical Medicine
1. Endocrine Metabolism
- Early diagnosis, intervention, and pathogenesis of chronic complications of diabetes (Direction 1)
2. Basic and Clinical Research on Intensive Insulin Therapy for Type 2 Diabetes (Direction 2)
Representative Papers (Last Five Years)
1. Hu Y, Ye S, Xing Y, Lv L, Hu W, Zhou W. Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats. Acta Diabetol. 2020; 57(3):279-286.
2. Zhou W, Ye S, Wang W, Li S, Hu Q. Clinical Features of COVID-19 Patients with Diabetes and Secondary Hyperglycemia. J Diabetes Res. 2020; 2020:3918723.
3. Xu J, Chen Y, Xing Y, Ye S. Metformin inhibits high glucose-induced mesangial cell proliferation, inflammation, and ECM expression through the SIRT1-FOXO1-autophagy axis. Clin Exp Pharmacol Physiol. 2019; 46(9):813-820.
4. Liu Y, Ye J, Cao Y, Zhang R, Wang Y, Zhang S, Dai W, Ye S. Silibinin ameliorates diabetic nephropathy via improving diabetic condition in mice. Eur J Pharmacol. 2019; 845:24-31.
5. Guangwei Yang, Yuanbo Wu, Shandong Ye. MiR-181c restrains nitration stress of endothelial cells in diabetic db/db mice through inhibiting the expression of FoxO1. Biochem Biophys Res Commun. 2017; 486(1):29-35.
6. Zheng M, Ye S, Chen Y, Chen M. A study of urinary Tamm-Horsfall protein excretion in adult type 2 diabetes mellitus. Clin Nephrol. 2018; 90(1):40-45.
7. Zhou W, Ye SD, Chen C, Wang W. Involvement of RBP4 in Diabetic Atherosclerosis and the Role of Vitamin D Intervention. J Diabetes Res. 2018; 2018:7329861.
8. Zhai L, Gu J, Yang D, Hu W, Wang W, Ye S. Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in type 2 diabetic rats. J Diabetes. 2017; 9(5):510-517.
Laboratory Website
Diabetes Research Laboratory
Contact Information
E-mail: ysd196406@163.com
Phone: 0551-62283346